

Updated as of June 10, 2003

Curriculum Vitae

MARC STUART ERNSTOFF, M.D.,

BIOGRAPHICAL

Name: Marc Stuart Ernstoff, M.D.

Business address: Dartmouth-Hitchcock Medical Center
Division of Hematology/Oncology
1 Medical Center Drive
Lebanon, NH 03756

Business phone: (603) 650-5534

EDUCATION AND TRAINING

Undergraduate: Emory University
Atlanta, Georgia

Graduate: New York University
School of Medicine
New York, New York

Postgraduate: Intern, Internal Medicine
Bronx Municipal Medical Center and
The Hospital of The Albert Einstein College of Medicine

Resident, Internal Medicine
Bronx Municipal Medical Center and
The Hospital of The Albert Einstein College of Medicine
New York, NY

Fellow in Medical Oncology
Yale University School of Medicine
New Haven, Connecticut

APPOINTMENTS AND POSITIONS

Professor of Medicine
Dartmouth-Hitchcock Medical Center, Lebanon, NH

CERTIFICATION

Diplomate, National Board of Medical Examiners
Diplomate, American Board of Internal Medicine
Diplomate, Subspecialty of Medical Oncology
Fellow, American College of Physicians

LICENSURE

New Hampshire

PROFESSIONAL ACTIVITIES

PUBLICATIONS

1) Refereed Articles:

1. **Ernstoff MS**, Fusi S, Kirkwood JM. Parameters of interferon action I. Immunological effects of whole cell leukocyte interferon (IFN alpha) in phase I-II trials. *J Biol Response Mod* 2(6):528-39, 1983.
2. **Ernstoff MS**, Fusi S, Rudnick S, Kirkwood JM. Parameters of interferon action II. Immunological effects of recombinant leukocyte interferon (IFN alpha-2) in phase I-II trials. *J Biol Response Mod* 2(6):540-47, 1983.
3. Coleman DL, **Ernstoff MS**, Kirkwood JM, Ryan JL. Effect of intravenous recombinant alpha-2 interferon on monocyte Fc dependent phagocytosis in patients with malignant melanoma. *J Interferon Res* 4:215-21, 1984.
4. **Ernstoff MS**, Kirkwood JM. Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. *Am J Med* 76:593-96, 1984.
5. Sumpio BE, **Ernstoff MS**, Kirkwood JM. Urinary excretion of interferon, albumin, and beta-2 microglobulin during interferon treatment. *Cancer Res* 44(8):3599-3603, 1984.
6. **Ernstoff MS**, Duray P, Stenn K, Kirkwood JM. Antigenic phenotype of pigmented lesions. *J Invest Dermatol* 84(5):430-32, 1985.
7. **Ernstoff MS**, Gallicchio V, Kirkwood JM. Analysis of granulocyte macrophage progenitor cells in patients treated with recombinant interferon alpha-2. *Am J Medicine* 79:167-170, 1985.
8. **Ernstoff MS**, Papac RJ. Carcinoma of unknown primary: A 20 year retrospective analysis. *Connecticut Medicine* 49(3):145-8, 1985.
9. Kirkwood JM, **Ernstoff MS**. Melanoma: Therapeutic Options with Recombinant Interferons. *Sem in Oncol* 12(4 Suppl. 5):7-12, 1985.
10. Kirkwood JM, **Ernstoff MS**, Davis CA, Reiss MJ, Rudnick SA. Comparative toxicity and antitumor effects of recombinant alpha-2 interferon administered by intramuscular and intravenous routes in 33 patients with melanoma and other cancers. *Annals of Int Med* 103(1):32-36, 1985.

11. Kirkwood JM, Harris JE, Vera R, Sandler S, Fischer DS, Khandekar J, **Ernstoff MS**, Gordon L, Lutes R, Bonomi P, Lytton B, Cobleigh M, Taylor SJ. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma. Am Cancer Soc Collaborative Trial. *Cancer Res* 45:863-71, 1985.
12. Roush GC, Barnhill RL, Duray PH, Titus LJ, **Ernstoff MS**, Kirkwood JM. Diagnosis of the dysplastic nevus in different populations. *J Am Acad Dermatol* 14(3):419-25, 1986.
13. Chan SM, Hoffer PB, Maric N, Zoghbi S, **Ernstoff MS**, Duray P, Kirkwood J, Gerich B. Ga-67 citrate versus In-111 monoclonal antibody for detection of melanoma in athymic mice. (33rd Annual Meeting, Soc Nuclear Medicine, June 22-June 25, 1986) *J Nucl Med* 28(9):1441-1446, 1987.
14. Cole S, Zawin M, Lundberg B, Hoffman J, Bailey L, **Ernstoff MS**. Candida epiglottitis in an adult with acute nonlymphocytic leukemia. *Am J Med* 82(3):662-664, 1987.
15. Lin JT, Cashmore AR, Baker M, Dreyer RN, **Ernstoff MS**, Marsh JC, Bertino JR, Whitefield LR, Delap R, Grillo-Lopez A. Phase I studies with trimetrexate: Clinical pharmacology, analytical methodology, and pharmacokinetics. *Cancer Res* 47:609-16, 1987.
16. Duray PH, **Ernstoff MS**. Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. *Archives of Dermatology* 123(1):80-84., 1987.
17. **Ernstoff MS**, Trautman T, Kirkwood JM, Davis CA, Reich S, Koval S, Witman P, Balzar J, Rudnick S. A randomized phase I/II study of continuous versus bolus infusion of recombinant interferon gamma in patients with metastatic melanoma. *J Clin Oncol* 5(11):1804-1810, 1987.
18. Kirkwood JM, Newmann RD, Zoghbi SS, **Ernstoff MS**, Cornelius EA, Shaw C, Ziyadeh T, Fine JA, Unger MW. Scintigraphic detection of metastatic melanoma using ¹¹¹indium-DTPA conjugated anti-gp240 antibody (ZME-018). *J Clin Oncol* 5(8):1247-1255, 1987.
19. Bahnsen RR, Ballou BT, **Ernstoff MS**, Schwentker FN, Hakala TR. Technique for catheterization and cystoscopic evaluation of cynomolgus monkey bladder. *Lab Animal Sciences* 38(6):731-733, 1988.
20. **Ernstoff MS**, Kirkwood JM. Immunotherapeutic approaches in the treatment and management of gastrointestinal malignancies. *Surg Rds* 11(11):63-74, 1988.
21. Kirkwood JM, **Ernstoff MS**. A clinical update: The role of interferon in the biotherapy of solid tumors. *Onc Nursing Forum* 1988 15(6):3-6, 1988.
22. Titus-Ernstoff L, Duray PH, **Ernstoff MS**, Barnhill RL, Horn PL, Kirkwood JM. Dysplastic nevi in association with multiple primary melanoma. *Cancer Research* 48(4):1016-1018, 1988.
23. Titus-Ernstoff L, **Ernstoff MS**, Kirkwood JM, Barnhill RL, Fine J, Duray PH. The usefulness of frequent skin examination for the early detection of second primary cutaneous melanoma. *Cancer Detect Prevent* 13(5-6):317-321, 1989.
24. **Ernstoff MS**. Synergistic actions of biological agents and chemotherapy. *Biotherapy & Cancer* 3:2-3, 1990.
25. Kirkwood JM, **Ernstoff MS**, Trautman T, Hebert G, Nishida Y, Davis CA, Balzer J, Reich S, Schindler J, Rudnick SA. *In vivo* biological response to recombinant interferon gamma during a phase I dose-response trial in patients with metastatic melanoma. *J Clin Oncol* 8(6):1070-1082, 1990.
26. Kirkwood JM, Logan TF, Vlock DR, **Ernstoff MS**. Biological response modifiers in the therapy of metastatic melanoma. *Pigment Cell* 10:105-40, 1990.
27. Bahnsen RR, **Ernstoff MS**, Miller RJ, O'Donnell WF. Toxicity comparison of neoadjuvant versus adjuvant methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) in radical cystectomy patients. *J Surg Oncol* 45(3):143-5, 1990.

28. Bahnsen RR, Slasky BS, **Ernstoff MS**, Banner BF. Sonographic characteristics of epidermoid cyst of the testicle. *Urology* 35(6):508-10,1990.
29. **Ernstoff MS**, Nair S, Bahnsen RR, Miketic LM, Banner B, Gooding W, Day R, Whiteside T, Hakala T, Kirkwood JM. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination rIFN gamma and rIFN alpha in patients with metastatic renal cell carcinoma. *J Clin Oncol* 8(10):1637-49,1990.
30. Kirkwood JM, **Ernstoff MS**. Role of interferon in the therapy of melanoma. *Intl J Dermatol* 95(6):180S-184S,1990.
31. Luger SM, Kirkwood JM, **Ernstoff MS**, Vlock DR. High dose cisplatin and dacarbazine in the treatment of metastatic melanoma. *JNCI* 82(24):1934-7,1990.
32. Banner BF, Brancazio L, Bahnsen RR, **Ernstoff MS**, Taylor SR. DNA analysis of multiple synchronous renal cell carcinomas. *Cancer* 66:2180-5,1990.
33. Bahnsen RR, Ballou BT, **Ernstoff MS**, Cramer DV, Schwentker FN, Reiland JM, Hakala TR. Toxicity of intravesical recombinant human tumor necrosis factor in cynomolgus monkeys. *J of Biol Response Mod* 9:445-7,1990.
34. Kirkwood JM, **Ernstoff MS**, Giuliano A, Gams R, Robinson WA, Costanzi J, Pouillat P, Speyer J, Grimm M, Spiegel R. Interferon alpha-2a and dacarbazine in melanoma. *J Natl Cancer Inst* 82:1062-3,1990.
35. Whiteside TL, **Ernstoff MS**, Nair S, Kirkwood JM, Herberman RB. *In vitro* generation and *in vivo* effects of adherent lymphokine activated killer A-LAK cells and IL2 in patients with solid tumors. 6th Intl Natural Killer Cell Workshop; Goslar, 1989. Basel, Karger, pub., 293-302,1990.
36. Miller RJ Jr, Bahnsen RR, Banner B, **Ernstoff MS**, O'Donnell WF. Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder. *Cancer*, Jan 15:65(2):207-10,1990.
37. Banner BF, Burhnam JA, Bahnsen RR, **Ernstoff MS**, Auerbach HE. Immunophenotypic markers in renal cell carcinoma. *Mod Path*, Mar:3(2):129-34,1990.
38. Banner BF, **Ernstoff MS**, Titus-Ernstoff L, Bahnsen RR, Taylor SK. Quantitative DNA analysis of small renal cortical neoplasms. *Human Pathology* 22(3):247-53,1991.
39. Logan TF, Kaplan SS, Bryant JL, **Ernstoff MS**, Krause JR, Kirkwood JM. Granulocytopenia in cancer patients treated in a phase I trial with recombinant human tumor necrosis factor (TNF). *J Immunother* 10(2):84-95,1991.
40. Titus-Ernstoff L, **Ernstoff MS**, Duray PH, Barnhill RL, Holubkov R, Kirkwood JM. A relation between childhood sun exposure and dysplastic nevus syndrome among patients with nonfamilial melanoma. *Epidemiology* 2(3):210-4,1991.
41. **Ernstoff MS**. Advances in the management of gastrointestinal malignancies. *Semin Oncol* 18(1):1-6,1991.
42. Herberman RB, **Ernstoff MS**, Kirkwood JM. Interferon alpha in combination with other biologics: the scientific rationale. *British J of Haematology*, Oct Suppl 1:78-80,1991.
43. Roush GC, Barnhill RL, **Ernstoff MS**, Kirkwood JM. Interclinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. *British Journal of Cancer*, Aug 64(2):373-6, 1991.

44. Sedlmayr P, Rabinowich H, Elder EM, **Ernstoff MS**, Kirkwood JM, Herberman RB, Whiteside TL. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine activated killer (A-LAK) cells. *J Immunother* 10:336-346,1991.
45. Bahnsen RR, Banner BF, **Ernstoff MS**, Lazo JS, Cherian MG, Banerjee D, Chin JL. Immunohistochemical localization of metallothionein in transitional cell carcinoma of the bladder. *J Urol* 146:1518-1520,1991.
46. **Ernstoff MS**, Jaffee EM, Oeler T. The development and characterization of a natural killer cell-resistant human renal cell carcinoma cell line. *Natural Immunity* 11 (1):17-25, 1992.
47. Nair S, **Ernstoff MS**, Bahnsen R, Arthur S, Johnson J, Downs MA, Neuhart J, Kirkwood JM. Interferon-induced reversible acute renal failure with nephrotic syndrome. *Urology* Vol. 39:169-172,1992.
48. **Ernstoff MS**, Gooding W, Nair S, Bahnsen RR, Miketic LM, Banner B, Day R, Whiteside T, Titus-Ernstoff L, Kirkwood JM. Immunological effects of treatment with sequential administration of recombinant interferons gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. *Cancer Res* 52(4):851-856,1992.
49. Fountain JW, Karayiorgou M, **Ernstoff MS**, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, Kidd VJ, Housman DE, Dracopoli NC. Homozygous deletions of human chromosome 9p21 in melanoma. *Proc Natl Acad Sci USA* 89:10557-10561, Nov 1992.
50. Barnhill RL, Roush GC, **Ernstoff MS**, Kirkwood JM. Interclinician agreement on the recognition of selected gross morphologic features of pigmented lesions. Studies of melanocytic nevi V. *J Am Acad of Dermatol* 26 (2 Pt 1):185-90, Feb 1992.
51. Barnhill RL, Roush GC, Titus-Ernstoff L, **Ernstoff MS**, Duray PH, Kirkwood JM. Comparison of nonfamilial and familial melanoma. *Derm* 184(1):2-7,1992.
52. Logan TF, Virji MA, Gooding WE, Bontempo FA, **Ernstoff MS**, Kirkwood JM. Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor. *J NCI* 84(23):1802-1810, Dec 1992.
53. Duray PH, DerSimonian R, Barnhill R, Stenn K, **Ernstoff MS**, Fine J, Kirkwood JM. An analysis of inter-observer reognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. *J Am Acad Derm*, 27 (5 PT 1):741-9,1992.
54. Selvaggi K, Saria EA, Schwartz R, Vlock DR, Ackerman S, Wedel N, Kirkwood JM, Jones H, **Ernstoff MS**. Phase I/II study of murine monoclonal antibody-ricin A chain (Xomazyme®-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. *J Immuno* 13(3):201-7, April 1993.
55. Titus-Ernstoff L, Barnhill RL, Duray PH, **Ernstoff MS**, Kirkwood JM. Dysplastic nevi in relation to superficial spreading melanoma. *Cancer Epidemiology, Biomarkers and Prevention* Mar-Apr;2(2):99-101,1993.
56. Logan TF, Shannon W, Bryant J, Kane P, Wolmark N, Posner M, Kirkwood JM, **Ernstoff MS**, Futrell JW, Straw LD, Iwatuski S, Bahnsen R, and the Tissue Bank of Pittsburgh Cancer Institute. Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. *Melanoma Research* 3:451-455,1993.
57. Kuo SM, Kondo Y, DeFilippo JM, **Ernstoff MS**, Bahnsen R, Lazo JS. Subcellular localization of Metallothionein IIA in human bladder tumor cells using a novel epitope-specific antiserum. *Toxicology and Applied Pharmacology* 125,104-110,1994.
58. **Ernstoff MS**. Combination cytokine therapy in cancer. *Immunol Ser*, 1994;61:273-9.
59. Logan TF, Virji MA, Gooding WE, Bontempo FA, **Ernstoff MS**, Kirkwood JM. Letter to the Editor: The pathogenesis of disseminated intravascular coagulation in sepsis. *JAMA* Feb 9;271(6):427-8,1994.

60. Agarwala SS, Bahnsen RR, Wilson J, Szumowski J, **Ernstoff MS**. Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma. *Am J Clin Oncol* 18(3):211-215, 1995.
61. Glazier DB, Bahnsen RR, McLeod DG, von Roemeling RW, Messing EM, **Ernstoff MS**. Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: An eastern cooperative oncology group study. *J Urology*, 154:66-68, July 1995.
62. Valone FH, **Ernstoff MS**, Guyre P, Kaufman PA, Lewis LD, Memoli V, Wells W, Schned A, Heaney J, Barth R, Deo Y, Fisher J, Phipps K, Graziano, R, Meyer L, Mrozek-Orlowski M, Wardwell W, Guyre V, Morley TL, Arvizu A, Wallace P, Dain B, Fanger MW. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. *J. Hematotherapy*, 1995 Oct;4(5):471-475.
63. Lattanzi SC, Tosteson T, Chertoff J, Maurer, LH, O'Donnell J, LeMarbre PJ, Mott L, DelPrete SA, Forcier, RJ, **Ernstoff MS**. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. *Melanoma Research*, 5:365-369, 1995.
64. Witte RS, Leong, T, **Ernstoff MS**, Krigel RL, Oken MM, Harris J, Tormey DC, Trump DL. A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma, *Investigational New Drugs* 13: 241-247, 1995.
65. Schned AR, Wheeler KJ, Hodorowski CA, Heaney JA, **Ernstoff MS**, Amdur RJ, Harris RD. Tissue shrinkage correction factor in the calculation of prostate cancer volume. *Am J Surg Pathol*, 1996 20(12): 1501-1506.
66. Kirkwood JM, Strawderman MH, **Ernstoff MS**, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 *Journal of Clinical Oncology* 1996 Jan;14(1):7-17.
French translation of above, Bordier, M (Medical Director), BLD Communication, Paris, 1/22/97.
67. Glazier DB, Heaney JA, Amdur RJ, Schned AR, Harris R, Fukui I, **Ernstoff MS**. 5-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase 1/II study. *Journal of Urology*, 1996 Feb;155(2):624-627.
68. Kaufman PA, Guyre PM, Lewis LD, Valone FH, Memoli V, Wells W, Deo YM, **Ernstoff MS**, Fisher J, Mrozek-Orlowski M, Phipps K, Fanger MW. HER-2/neu Targeted Immunotherapy: A Pilot Study of Multi-Dose MDX-210 in Patients with Breast or Ovarian Cancers that Overexpress HER-2/neu and a Report of an increased incidence of HER-2/neu Overexpression in Metastatic Breast Cancer. *Tumor Targeting*, 2:17-28, 1996.
69. Caubet JF, Tosteson TD, Dong EW, Naylor E, Whiting GW, **Ernstoff, MS** and Ross S. Maximum Androgen Blockage in Advanced Prostate Cancer: A Meta-analysis of Published Randomized Controlled Trials Using Non-Steroidal Anti-Androgens. *Urology*. July, 1996.
70. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) Randomized Trial of Pre-enucleation Radiation of Large Choroidal Melanoma: I. Characteristics of Patients Screened for Eligibility: COMS Report No. 5, November, 1996.
71. Cardi G, Ciardelli TL, **Ernstoff MS**. Therapeutic applications of cytokines for immunostimulation and immunosuppression: An update. *Progress in Drug Research*, 47: 211-250, 1996.
72. Cardi G, Heaney JA, Schned AR, Phillips DM, Branda M, **Ernstoff MS**. T-cell Receptor zeta chain Expression on Tumor Infiltrating Lymphocytes from Renal Cell Carcinoma. *Cancer Research*, 57(16):3517-9, 1997.

73. Logan T, Gooding W, Whiteside T, **Ernstoff, MS**, Kaplan S, Miketic, L, Vlock DR, Tompkins C, Wood D, Nadler P, Kirkwood JM. Biological Response Modulation by Tumor Necrosis Factor Alpha (TNF α) in a Phase Ib Trial in Cancer Patients, *J of Immunology*, 20(5):387-398, 1997.
74. Schwaab T, Atzpodien J, Heaney JA, **Ernstoff MS**. In Vivo-Beschreibung tumorinfiltrierender Dendritischer Zellen (TiDCs) im humanen Nierenzellkarzinom (NCC) - Phaenotyp und Funktion, Deutsche Gesellschaft fur Urologie, 1998.
75. Cardi G, Heaney JA, Schned AR and **Ernstoff MS**. Expression of Fas(APO-1/CD95) in Tumor Infiltrating and Peripheral Blood Lymphocytes in Patients with Renal Cell Carcinoma, *Cancer Research*, 58(10):2078-80,1998.
76. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, **Ernstoff MS** and Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide, *Prostate Cancer and Prostatic Diseases*, 5:1-5, 1998.
77. **Ernstoff MS**, Voting Member of Collaborative Ocular Melanoma Study Group, Data and Safety Monitoring Committee, Histopathologic Characteristics of Uveal Melanomas in Eyes Enucleated from the Collaborative Ocular Melanoma Study, Collaborative Ocular Melanoma Study Randomized Trial or Pre-enucleation Radiation of Large Choroidal Melanoma I: Characteristics of patients enrolled and not enrolled, and Collaborative Ocular Melanoma Study Randomized Trial of Pre-Enucleation Radiation of Large Choroidal Melanoma II: Initial Mortality Findings, *American Journal of Ophthalmology*, 125:6, June, 1998.
78. Logan TF, Banner B, Rau U, **Ernstoff MS**, Wolmark N, Whiteside TL, Miketic L, Kirkwood JM. Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy, *Clinical and Experimental Immunology*, 114:347-354, 1998.
79. Schwaab T, Schned AR, Heaney JA, Cole BF, Atzpodien J, Wittke F, **Ernstoff, MS**. In Vivo Description of Dendritic Cells in Human Renal Cell Carcinoma. *Journal of Urology*, 162(2):567-73, 1999.
80. Chapman, PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg, CB, Agarwala SS, Schuchter LM, **Ernstoff MS** et al, Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients with Metastatic Melanoma, *J of Clin Oncol*, in press.
81. Givan AL, Fisher JL, Waugh M, **Ernstoff MS**, and Wallace PK. A Flow Cytometric Method to Estimate the Precursor Frequencies of Cells Proliferating in Response to Specific Antigens, *J Immunol Methods*, 230(1-2):99-112, 1999.
82. Schwaab T, Heaney J, Schned AR, Harris RD, Cole BF, Phillips D, **Ernstoff MS**, Stempkowski, L. A Randomized Phase II Trial Comparing Two Sequence Combinations of Autologous Vaccine and Human Recombinant Interferon γ and Human Recombinant Interferon α -2BTherapy in Patients with Metastatic Renal Cell Carcinoma: Clinical Outcome and Analysis of Immunological Parameters, *J of Urol*, 2000.
83. Spitler LE, Grossbard ML, **Ernstoff MS**, Silver G, Jacobs M, Hayes FA, Soong SJ, Adjuvant Therapy of Stage III and IV Malignant Melanoma Using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), *J Clin Oncol*, 18 (8):1614-1621, 2000.
84. **Ernstoff MS**. Melanoma. Screening and education. *Clinics in Plastic Surgery*. 27(3):317-22, vii, 2000 Jul.
85. Kirkwood JM, Ibrahim J, Sondak VK, Richards J, Flaherty LE, **Ernstoff MS**, Smith TJ, Rao U, Steele M and Blum RH. High and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup trial E1690/S9111/C9190, *J Clin Oncol*, 18(12): 2444-58, 2000.
86. Collaborative Ocular Melanoma Study (COMS) Group, Consistency of Measurements and Observations from Echograms made Centrally in the Collaborative Ocular Melanoma Study, COMS Report No. 13, 2000.

87. Noll WW, Belloni DR, Rutter JL, Storm CA, Schned AR, Titus-Ernstoff L, **Ernstoff, MS**, Birnckerhoff CE. Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter, Am J Pathol 2001.
88. Lewis LD, Cole BF, Wallace PK, Fisher JL, Waugh M, Guyre PM, Fanger MW, Curnow RT, Kaufman PA, **Ernstoff MS**. Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with Interferon gamma in a multiple-dose Phase I study in patients with advanced cancer which overexpresses Her-2/neu. J Immunol Methods (Spec. Ed.), 248:149-165, 2001.
89. Wallace PK, Tsang KY, Goldstein J, Correale P, Schlom J, Guyre PM, **Ernstoff MS**, Fanger MW. Exogenous Antigen Targeted to Fc γ RI on Myeloid Cells is Presented in Association with MHC Class I, J of Immunological Methods 2000, 248: 183-194.
90. Wallace PK, Kaufman PA, Lewis LD, Keler T, Givan AL, Fisher JL, Waugh MG, Wahner AE, Guyre PM, Fanger MW, **Ernstoff MS**. Bispecific Antibody-Targeted Phagocytosis of HER-2/neu Expressing Tumor Cells by Myeloid Cells Activated *in Vivo*, J of Immunological Methods 2001 248: 167-182.
91. Schwaab T, Lewis L, Cole BF, Deo Y, Fanger, MW, Wallace P, Guyre PM, Fisher JL, Waugh MG, Phipps KJ, Kaufman PA, Heaney JA, Schned AR, Harris RD, **Ernstoff MS**. Phase I trial of the Bispecific Antibody MDXH210 (anti-Fc γ RI X anti-HER-2/neu) in Hormone Refractory Prostate Patients Whose Cancer Overexpresses HER-2/neu. J of Immunotherapy 24(1):79-87, 2001.
92. Margolin K, Thompson John A, Clark Joseph I, Flaherty Lawrence, Atkins Michael B, Sosman Jeffrey, Weiss Geoffrey, **Ernstoff Marc**, Weber Jeffrey, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group, 2001, also published online J Cancer Res Clin Oncol 128:214-218 DOI 10.1007/s00432-002-0323-8, 2002.
93. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, **Ernstoff MS**, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial 1694/S9512/C509801. Journal of Clinical Oncology. 19(9):2370-80, 2001.
94. Kirkwood JM, Ibrahim J, Manola J, Sondak VK, **Ernstoff MS**, Agarwala SS. Response to Letters to the Editor of a) L. Kretschmer and C. Neumann, Dept of Dermatology, University of Gottingen, Gottingen, Germany and b) B. Coldiron and S. Dinehart, Arkansas Cancer Research Center, Little Rock, AR, concerning "High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival...in patients with resected stage IIb-III melanoma." JCO, 2002.
95. Rosenberg HJ, Rosenberg SD, **Ernstoff MS**, et al. Expressive Disclosure and Health Outcomes in a Prostate Cancer Population, The International Journal of Psychiatry in Medicine, 32(1):37-53, 2002.
96. Lewis LD, Beelen AP, Cole BF, Wallace PK, Fisher JL, Waugh MG, Kaufman PK, **Ernstoff MS**. Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer overexpresses HER-2/neu. J Immunol Methods. 248:149-65, 2001.
97. Fadul CE, Wallace PK, Pipas JM, Roberts DW, Cole BF, Meyer LP, Rhodes HR, **Ernstoff MS** and Fanger MW. Phase I Trial of Bispecific Antibody Armed Macrophage Activated Killer Cells in Patients with Glioblastoma Multiforme. Poster presentation at the First Quadrennial Meeting of the World Federation of Neuro-Oncology 11/15-18, 2001, Washington, DC. Sponsored by the Society for Neuro-Oncology and The University of Texas M.D. Anderson Cancer Center.
98. Guyre Cheryl A, Fisher Jan L, Waugh Mary G., Wallace Paul K, Treter Christopher G, **Ernstoff Marc S**, Barth Richard J. Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications. J Immunol Methods, (in press) 2002.
99. Lewis LD, Beelen AP, Cole BF, Wallace PK, Fisher JL, Waugh MG, Kaufman PA, **Ernstoff MS**. The

pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer. Springer-Verlag, Berlin, Published online: 7 February 2002.

100. Lewis LD, Beelen AP, Cole BF, Wallace PK, Fisher JL, Waugh MG, Kaufman PA, **Ernstoff MS**. The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer. *Cancer Chemother Pharmacol*. 49(5):375-84, May 2002.
101. Tran TP, Titus-Ernstoff L, Perry AE, **Ernstoff MS**, Newsham IF. Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression. *Cancer Causes & Control*. 13(7):675-82, 2002.
102. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, **Ernstoff MS**, Letter to the Editor regarding Lens and Dawes Article, *Journal of Clinical Oncology*
102. Bukowski R, **Ernstoff MS**, Gore ME, Nemunaitis JJ, Amato R et al. Pegylated Interferon alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study, *J Clin Onc*, 20(18): 3841-3949, Sept 2002.
103. Witte RS, Leong T, **Ernstoff MS**, Krigel RL, Oken MM, Harris J, Tormey DC, Trump DL. A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma, *Investigational New Drugs*, 13(3): 241-7, Jan 1995.
104. Guyre CA, Fisher JL, Waugh MG, Wallace PK, Tretter CG, **Marc S. Ernstoff**, Barth RJ. Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications, *Journal of Immunological Methods*, 262(2002) 85-94.
105. Waller EK, **Ernstoff, MS**. Modulation of Anti-Tumor Immune Responses by Hematopoietic Cytokines. *Cancer* (in press).
106. Nadege Bercovici, Alice L. Givan, Mary Waugh, Jan Fisher, Rederique Vernel-Pauillac, **Marc S. Ernstoff**, Jean-Pierre Abastado, and Paul K. Wallace. Multiparameter Precursor Analysis of T-cell Responses to Antigen. *Journal of Immunologic Methods* (in press).
107. Janice P. Dutcher, Jason P. Fine, Robert L. Krigel, Barbara A. Murphy, Paul L. Schaefer, **Marc S. Ernstoff**, Patrick J. Loehrer, Sr. (in press)

2) Reviews, Invited Published Papers, Monographs, Books and Chapters:

1. **Ernstoff MS**, Cadman EC. Treatment of cerebral metastases. *Connecticut Medicine* 1982;46(6):310-12.
2. Kirkwood JM, **Ernstoff MS**, Fusi S, Davis CA, Ariyan S, Rudnick SA. Toxicity and antitumor effects of recombinant alpha-2 interferon in a phase I trial by the intramuscular route. *Proc. XIII Int. Cong. of Chemotherapy*, Vienna, Austria, SE 12.5.4, 45-48, 1983.
3. Kirkwood JM, **Ernstoff MS**. Review: Interferons in the treatment of cancer in man. *Journal of Clin Onc* 1984; 2(4):336-52.
4. **Ernstoff MS**, Kirkwood JB. Review: Interferons as anti-cancer agents. *Mod Med of Can* 1985;40(9):863-867.
5. Kirkwood JM, **Ernstoff MS**. Interferon in urologic malignancies. (Garnick M.B., ed) In: Genitourinary Cancer, Churchill Livingstone, Inc., New York, NY 1985; 225-41.
6. Kirkwood JB, **Ernstoff MS**. Potential applications of the interferons in oncology: Lessons drawn from studies of human melanoma. *Seminars in Oncology* 1986; 13(3, Suppl 2):48-56.

7. Kirkwood JM, **Ernstoff MS**. The role of interferon in the management of melanoma. (Nathanson L., ed) In: Management of Advanced Melanoma, Churchill Livingstone, Inc., New York, NY 1986; 209-223.
8. Rousch GC, Kirkwood JM, **Ernstoff MS**, Somma SJ, Duray PH, Klaus SN, Stenn KS, Titus LJ, Lerner AB. Reproducibility and validity in the clinical diagnosis of the non-familial dysplastic nevus: work in progress. Recent Results Cancer Res 1986;102:153-8.
9. Kirkwood JM, **Ernstoff MS**. Interferons in cancer therapy. (Kimura K, Ota K, Herberman RB, Takita H, ed) In: Cancer Chemotherapy Challenges for the Future Vol. 2, International Congress Series, Excerpta Medica, Princeton, NJ, 1987;16-23.
10. Kirkwood JM, **Ernstoff MS**. Editorial: Coumarin plus cimetidine - yet another angle for therapy of renal cell carcinoma. J Clin Oncol 1987; 5(6):836-37.
11. **Ernstoff MS**, Titus-Ernstoff L, Duray PH, Kirkwood JM. Lymph node dissection as indicated in the evaluation of limited malignant melanoma. (Gitnick G, ed). In: Debates in Medicine, Yearbook Medical Publishers, Chicago IL, 192-220,1988.
12. Titus-Ernstoff, **Ernstoff MS**, Kirkwood JM, Duray PH. Response to Dr. David August's position for prophylactic lymph node dissection in patients with clinical stage I disease. In: Debates in Medicine(Vol. I), Ed: T. Duffy. Yearbook Medical Publishers, Chicago, IL, 1988.
13. **Ernstoff MS**, Lembersky BC, Kirkwood JM. Fluorouracil, interferon-alpha and colon cancer: rational pursuit of synergism between antimetabolites and biologicals (editorial; comment). J Clin Oncol Dec;7(12):1764-5, 1989.
14. **Ernstoff MS**, Bahnsen RR, Hakala T. Tumor necrosis factor alpha: A potential anti-cancer agent for superficial bladder cancer. Surgical Rounds, 1990.
15. Duray PH, **Ernstoff MS**, Titus-Ernstoff L. Immunohistochemical phenotyping of malignant melanoma: A procedure whose time has come in pathology practice. (Sommers, Rosen, eds) In: Pathology Annual, 1988 Appleton Century Crofts, New York, NY 1990: Part II, 351-377.
16. Heberman RB, Basse P, Jain RK, Medler RJ, Goldfarb RH, Gorelik E, **Ernstoff MS**, Kirkwood JM, Whiteside TL. Approaches to immunotherapy with defined populations of IL-2 cultured NK cells, immune T cells or tumour infiltrating lymphocytes. (Rees RC, ed) In: The Biological and Clinical Applications of Interleukin-2, Oxford: IRL Press, 1990, 111-119.
17. Kirkwood JM, **Ernstoff MS**. Interferons in the therapy of cutaneous melanoma. (DeVita VT Jr., Hellman S, Rosenberg SA, eds.) In: Biologic Therapy of Cancer, Philadelphia: JB Lippincott Co., 1991, 311-333.
18. Kirkwood JM, **Ernstoff MS**. The role of interferons in the therapy of melanoma. (Hersey P., ed) In: Biological Agents in the Treatment of Melanoma and Other Cancers: Proceedings of the International Conference held in Newcastle, Sept. 4-7, 1990. Newcastle, NSW. Government Printing 1990; 303-322.
19. Kirkwood JM, **Ernstoff MS**, Vlock DR, Opacic D, Boucher Y, Jain R. A synthesis of biological approaches to melanoma under study at the Pittsburgh Cancer Institute. (Hersey P., ed) In: Biological Agents in the Treatment of Melanoma and Other Cancers: Proceedings of the International Conference held in Newcastle, Sept. 4-7, 1990. Newcastle, NSW. Government Printing 1990; 527-533.
20. Kirkwood JM, **Ernstoff MS**, Vlock DR, Herberman RB, Whiteside TL. New approaches to the use of IL-2 in melanoma: adoptive cellular therapy utilizing purified populations of A-LAK effectors. (Hersey P, ed) In: Biological Agents in the Treatment of Melanoma and Other Cancers: Proceedings of the International Conference held in Newcastle, Sept. 4-7, 1990. Newcastle, NSW. Government Printing 1990; 40-46.
21. **Ernstoff MS**, Hakala T. Deeply invasive transitional cell carcinoma. B.C. Decker, Inc. Mosby-Year Book. In: Current Therapy in Genitourinary Surgery, 78-80, 1992.

22. **Ernstoff MS.** Immunotherapy of Renal Cell Carcinoma. (Rous SN, ed.) In: 1994 Urology Annual Vol. 8. Norton Medical Books, W. W. Norton Co., New York, 1994, 145-58.
23. **Ernstoff MS**, Bahnsen RR, Heaney JA. Genitourinary Cancers Protocols. In: Current Cancer Therapeutics. NCI, 1994.
24. **Ernstoff MS.** Combination Cytokine Therapy in Cancer. (Goldfarb RH, Whiteside TL, eds.) In: Tumor Immunology and Cancer Therapy. New York: Marcel Dekker, Inc., 1994, 273-279.
25. Bahnsen R, Becich M, **Ernstoff MS**, Sandlow J, Cohen MB, Williams RD. Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. *J of Urol*, 152:2272-5, 1994.
26. Meehan KR, **Ernstoff MS.** Paraneoplastic syndromes. In: Cecil Textbook of Medicine, 19th edition, 1995.
27. Gorsch SM, **Ernstoff MS.** Management of metastatic renal cell carcinoma: Chemotherapy, hormonal therapy and interferons. In: Vogelzang NJ, Miles BJ, eds. Comprehensive Textbook of Genitourinary Oncology. Baltimore: Williams & Wilkins, October 1995.
28. **Ernstoff MS**, Bahnsen RR, Heaney JA. Genitourinary cancer. Current Cancer Therapeutics, ed. Kirkwood JM, 2nd ed, Philadelphia, 1996, 198-214.
29. Gorsch SM, **Ernstoff MS.** Biologic therapy of renal cell carcinoma. In: Ernstoff MS, Heaney JA, Peschel RE. Urologic Cancer. Boston: Blackwell Science, 1996.
30. Meehan KR, **Ernstoff MS.** Paraneoplastic syndromes. In: Cecil Textbook in Medicine, 20th edition. W.B. Saunders:Philadelphia. 1996, 1017-1021.
31. Borden EC, Crawford J, Cross A, Dillman RO, **Ernstoff MS**, Hawkins MJ and Heyman M. The Chemotherapy Sourcebook, Chapter 43, "Toxicity of Biologic Response Modifiers", Williams and Wilkins, 1996, 833-841.
32. Amdur RJ, Leopold KA, **Ernstoff MS**, Schned AR, Heaney JA. Using PSA Response to Predict Outcome Following Radiotherapy for Prostate Cancer In: Rous S (Ed.) Urology Annual 1997 (volume 11), W.W. Norton & Co., Inc. New York, NY, 25-37.
33. Tretter, C, Heaney JA, Amdur RJ, **Ernstoff MS.** Genitourinary Cancer. Chapter 14 in: Current Cancer Therapeutics, 3rd edition. ed. Kirkwood JM, Lotze MT, Yasko JM, Philadelphia, 1998, 199-217.
34. The Collaborative Ocular Melanoma Study (COMS) Randomized Trial of Pre-enucleation Radiation of Large Choroidal Melanoma III: Local Complication and Observations Following Enucleation COMS Report No. 11, Elsevier Science Inc., American Journal of Ophthalmology, September, 1998.
35. **Ernstoff MS**, Meehan K. "Nonmetastatic Effects of Cancer: Other Systems" in 21st edition of the Cecil Textbook of Medicine, 1999.
36. **Ernstoff MS** and Heaney JA. Urethral Carcinoma. Eds. Gomella L and Damba, M, Williams and Wilkins, Baltimore, MD, 1999.
37. Contributor: Division of Information Development, Drug Information for the Health Care Professional, USP DI 19th Edition, Micromedex, Inc, Englewood, CO, 1999.
38. Curtis MR, Heaney JA, Amdur RJ, Schned AR, Harris R, **Ernstoff MS.** Prostate Carcinoma, Ch 6 in Strategies in Adjuvant Therapy, ed. JM Kirkwood, 105-131, Feb 2000.
39. Kirkwood, JM, Ibrahim, J, Sondak VK, Flaherty LE, Smith TJ, Steele M, Richards, J, **Ernstoff MS**, Rao, U, Blum RH. Letter to the Editor, Adjuvant Interferon in the Treatment of Melanoma, *Brit J of Cancer*, 1999.

40. Ernstoff, MS. "Prostatic carcinoma", in Strategies in Adjuvant Therapy , ed. JMKirkwood. Martin Dunitz Ltd, London, pg 2-26, 1999.
41. Curtis MR, Heaney JA, Amdur RJ, Schned AR, Harris R, **Ernstoff MS**. Prostate Carcinoma, Ch 6 in Strategies in Adjuvant Therapy, ed. JM Kirkwood, 105-131, 2000.
42. Treter C, Savage Paul D, Muss Hyman B, **Ernstoff Marc S**. Interferon- α and - β : Clinical Applications Renal Cell Cancer, Chapter 10.3 in Principles and Practice of the Biologic Therapy of Cancer, Ed., Steven A. Rosenberg, Third Ed. Lippincott Williams & Wilkins, 2001.
43. **Ernstoff, MS**. "Clinical Aspects of Prostate Cancer", Chapter in Atlas of the Prostate, Ed. Reginald C. Bruskewitz, MD, Current Medicine, Inc., Philadelphia, PA, 2002.
44. **Ernstoff MS**. Melanoma. Screening and education Clinics in Plastic Surgery. 27(3):317-22, vii, 2000 Jul

3) Editor

1. Editors: **Ernstoff MS**, Heaney JA, Peschel RE. Urologic Cancer. Blackwell Science, Boston MA, 1997.
2. Editors: **Ernstoff**, Heaney, and Peschel, Prostate Cancer. 1998: Blackwell Science.
3. Editors: **Ernstoff**, Heaney, and Peschel, Testicular and Penile Cancer. 1998: Blackwell Science.

4) Published Abstracts:

1. **Ernstoff MS**, Hebert GZ, Kirkwood JM. Parameters of interferon action. Natural killer (NK) activation during a phase II trial. Proc AACR Abstr 23:247,1982.
2. Fusi S, Hebert GZ, Ariyan S, **Ernstoff MS**, Kirkwood JM. Parameters of interferon action: T cell subsets and NK function during a phase I trial of recombinant human interferon alpha-2. Proc AFCR Abstr 30:A 694,1982.
3. **Ernstoff MS**, Davis CA, Ferraresi RW, Rudnick S, Kirkwood JM. Toxicity and antitumor effects of daily recombinant human interferon alpha-2. Proc AFCR 39(3):A 694,1982.
4. Kirkwood JM, **Ernstoff MS**, Rudnick SA, Davis CA, Fusi S, Hebert GZ, Marsh JC. Intramuscular recombinant interferon alpha-2 in a phase I immunopharmacological study in man. Proc ASCO 19(2):C-233,1982.
5. **Ernstoff MS**, Reiss M, Davis CA, Rudnick SA, Kirkwood JM. Intravenous recombinant alpha-2 interferon in metastatic melanoma. Proc ASCO 19(2):C-222,1982.
6. Coleman D, **Ernstoff MS**, Ryan J, Kirkwood JB. Modulation of monocyte Fc dependent phagocytosis by intravenous alpha-2 interferon in patients with malignant melanoma. 5th Int Cong of Immunol,1983.
7. **Ernstoff MS**, Reiss M, Davis CA, Rudnick SA, Kirkwood JM. Intravenous recombinant alpha-2 interferon in metastatic melanoma. Proc ASCO (2):C-222.,1983.
8. Coleman D, **Ernstoff MS**, Ryan J, Eckstein H, Kirkwood JM. Effect of intravenous alpha-2 interferon on monocyte Fc dependent phagocytosis in patients with malignant melanoma. Proc AFCR 31:340A,1983.
9. Sumpio BE, **Ernstoff MS**, Kirkwood JM. Interferon-induced proteinuria. Proc 16th Annual Meeting Am Soc Nephrology, Dec 4-7, 1983. Pub. in Kidney Int 25:238,1984.
10. Kirkwood JM, Herbert Z, Nishida Y, **Ernstoff MS**, Williams RGB, Vera R. Oligo 2'5 adenylate synthetase (2'5As) induction with human leukocyte and recombinant alpha interferon (IFN). Proc ASCO 3:C-241,1984.

11. **Ernstoff MS**, Davis CA, Kirkwood JM. Cimetidine (C) plus interferon alpha-2 (IFN) does not remit metastatic melanoma which has failed IFN alone. Proc ASCO 3:C-240,1984.
12. **Ernstoff MS**, Davis CA, Kirkwood JM. A phase II trial of intermittent human leukocyte interferon (HuLeIFN) in patients with metastatic melanoma. Sponsored by the American Cancer Society. Proc ASCO 3:C-242,1984.
13. **Ernstoff MS**, Chee D, Witman G, Kirkwood JM. The expression of p97, kd250, DR and beta-2 Microglobulin (B2m) cell surface antigen in cycling melanoma cells in culture. Proc AFCR 32(2):345A,1984.
14. Robinson WA, Kirkwood JM, Harvey H, McCune C, Muggia F, Hawkins M, Muscato M, Pouillat P, **Ernstoff MS**, Sorell M, Spiegel R. Effective use of recombinant human alpha-2 interferon in metastatic malignant melanoma: A comparison of two regimens. Proc ASCO 3:C-234,1984.
15. Lin J, **Ernstoff MS**, Cashmore A, Marsh JC, Bertino JR, DeLap RJ, Grillo-Lopez AJ. A phase I study of trimetrexate. Proc ASCO 4:C-114,1985.
16. Duray PH, **Ernstoff MS**, Stenn KS, Levy A, Clark WH, Jr., Kirkwood JM. Quality control in the histologic diagnosis of nevo-melanocytic lesions. Proc ASCO 4:C-81,1985.
17. **Ernstoff MS**, Roush G, Barnhill R, Duray P, Titus L, Fine J, Stenn K, Kirkwood JM. Interobserver agreement and correlation of pathology with clinical diagnosis of dysplastic (DN) and nondysplastic nevi (NN) in melanoma patients (PT). Proc ASCO 4:C-75,1985.
18. Roush G, Titus LJ, **Ernstoff MS**, Barnhill R, Klaus S, Lerner A, Duray PH, Stenn K, Kirkwood JM. Pigmentary risk factors for biopsy-proven dysplastic nevi in non-familial melanoma. Proc ASCO 4:C-77,1985.
19. Kirkwood JM, Neumann RD, Zoghbi SS, **Ernstoff MS**, Ziyadeh T, Fine JA, Shaw C, Unger MW. Radioimmunoassay of metastatic melanoma with indium-111-DTPA conjugated anti GP-240 monoclonal antibody ZME-018 (MOAb). Proc AACR 26:1167(296),1985.
20. Kirkwood JM, Nordlund J, Lerner A, **Ernstoff MS**, DerSimonian R, Fine J, Melia M, Forget B, Vlock DR. Favorable prognosis of melanoma associated with hypopigmentation (HYP) in a randomized adjuvant trial comparing DTIC-BCG (DB) vs. monobenzyl ether of hydroquinone (HQ) vs. null (NL) treatment. Proc ASCO 4:C-581,1985.
21. Neumann RD, Kirkwood JM, Zoghbi SS, **Ernstoff MS**, Cornelius EA, Hoffer PB, Gottchalk A. Ga-67 vs. In-111-DTPA-Anti-p97 monoclonal antibody (MoAb) for scintigraphy detection of metastatic melanoma. J Nuclear Med 26:15,1985.
22. **Ernstoff MS**, Reich S, Nishida Y, Kirkwood JM. Immunological assessment of melanoma patients treated with recombinant interferon gamma (rIFN gamma, Biogen, Inc., Cambridge, MA) in a phase I/II trial. Proc AACR 26:1102(280),1985.
23. Trautman T, Kirkwood JM, **Ernstoff MS**, Davis C, Coval S, Reich S, Rudnick S, Fischer D. Phase I-II trial of recombinant interferon gamma (IFN gamma) by 2 or 24 hr. Infusion in 30 melanoma patients. Proc ASCO 4:C-905,1985.
24. Duray P, **Ernstoff MS**, Stenn KS, Kirkwood JM. Antigenic phenotyping of nevomelanocytic lesions including dysplastic nevo. Lab Investigation 52:20A,1985.
25. Barnhill R, Kirkwood JM, Roush GC, **Ernstoff MS**, Titus LJ, Duray PH, Stenn K, Fine JA. Clinical and pathological features of least and most atypical nevi in melanoma patients. Proc ASCO C-589,1985.

26. Roush GC, Titus LJ, Barnhill RL, **Ernstoff MS**, Duray PH, Kirkwood JM, Lambert S. Prediction of histologically dysplastic melanocytic nevi from clinical and epidemiologic information. Proc Am Fed Clin Res (AFCR), Published in Clin Res 34(2):418A,1986.
27. Barnhill RL, Duray PH, Roush GC, Titus L, **Ernstoff MS**, Kirkwood JM. Correlation of histologic architectural features with nuclear atypia in atypical (dysplastic) melanocytic nevi. Proc Am Fed Clin Res (AFCR), published in Clin Res 34(2):736A,1986.
28. Schnall SF, Davis S, Ziyadeh T, Kirkwood JM, Pasquale D, Bobrow S, Schnipper E, **Ernstoff MS**. Treatment of metastatic renal cell carcinoma (RCC) with intramuscular (IM) recombinant interferon alpha A (IFN, Hoffman-LaRoche). Proc ASCO (ASCO 22nd Annual Meeting) 5:227 (Abstr. 890),1986.
29. **Ernstoff MS**, Duray PH, Barnhill R, Roush G, Gerich B, Lambert S, Titus L, Kirkwood JM. Patterns of antigen expression in the most typical and most atypical nevi removed from cutaneous melanoma (CM) patients (pt). Proc ASCO (ASCO 22nd Annual Meeting) 5:11 (Abstr. 44),1986.
30. Titus L, Roush GC, Barnhill R, Duray PH, **Ernstoff MS**, Fine J, Kirkwood JM, Lambert S. Sunlight and histologically confirmed dysplastic nevi. Proc ASCO (ASCO 22nd Annual Meeting) 5:215 (Abstr. 843),1986.
31. Duray P, Kacinski B, Bloodgood R, **Ernstoff MS**, Barnhill R, Kirkwood JM, Roush G. Growth factor oncogenes and tumor associated antigens: A study of lesions of nevomelanocytes. U.S. Canadian Academy of Pathology Annual Meeting in Chicago, IL. March 1987. Lab Investigation, 56:21A (Abstr. 119),1987.
32. Logan TF, **Ernstoff MS**, Kirkwood JM, Gerich B, Friberg D, Whiteside T, Eddy B, Witman P, Schindler J, Herberman RB, Reich S. Changes in natural killer cell (NK) phenotype in peripheral blood (PB) of patients (PT) with renal cell carcinoma and melanoma treated with recombinant interferon gamma (IFN-gamma). Proc Am Assoc Cancer Res (AACR 78th Annual Meeting) 78:2520 (Abstr. 2520),1987.
33. Nair SG, Schwarz RE, **Ernstoff MS**, Melder R, Hiserodt JC, Elder E, Bahnsen R, Herberman RB, Gemperlein M, Whiteside TL, Kirkwood JM. Factors correlated with the generation of adherent lymphokine activated killer cells (ALAK) in patients (PTS) with metastatic melanoma (MEL) and renal cell carcinoma (RCC). Proc Am Soc Clin Oncol (ASCO 23rd Annual Meeting) 8:195 (Abstr. 759),1989.
34. Szumowski J, **Ernstoff MS**, Bahnsen R, Downs M, Neuhart J, Banner B, Miketic L. Chemotherapy (vinblastine, V) and inhibitor (quindine sulfate, Q) multidrug resistance (MDR) in the treatment of metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol (ASCO 23rd Annual Meeting) 8:145 (Abstr. 565),1989.
35. Roth A, Zajko A, Vlock D, **Ernstoff MS**, Futrell W, Opacic D, Gemperlein M, Kirkwood JM. A phase IB study of intralymphatic (IL) or intradermal (ID) recombinant interleukin 2 (IL2) in patients (PTS) with in transit local-regional metastatic melanoma. Proc Am Soc Clin Oncol (ASCO 23rd Annual Meeting) 8:289 (Abstr. 1127),1989.
36. Logan TF, Virji MA, Kirkwood JM, **Ernstoff MS**, Whiteside TL, Bontempo FA, Prescott K, Wood D, Nadler P. Tumor necrosis factor effects on NK activity, LAK generation, PMN-induced growth inhibition vs. DAUDI, tissue plasminogen activator/inhibitor induction and granulocyte kinetics observed in a phase I trial. Proc Am Soc Clin Oncol (ASCO 23rd Annual Meeting) 8:195 (Abstr. 758),1989.
37. Titus-Ernstoff L, **Ernstoff MS**, Duray PH, Barnhill RL, Holubhkov R, Kirkwood JM. Wine consumption associated with dysplastic nevi in melanoma patients. Proc Am Soc Clin Oncol (ASCO 23rd Annual Meeting) 8:96 (Abstr. 371),1989.
38. **Ernstoff MS**, Tayyeb J. Development of resistance to natural killer cell (NK) cytotoxicity in human renal cell carcinoma (RCC) in cell lines. Proc Am Assoc Cancer Res. (AACR Annual Meeting) 30:337 (Abstr. 1337),1989.

39. Whiteside TL, **Ernstoff MS**, Kirkwood JM, Herberman RB. In Vivo effects of adherent lymphokine adherent killer (ALAK) cells and IL2 in patients with solid cancer. CIS Abstracts.
40. **Ernstoff MS**, Nair S, Bahnsen R, Gooding W, Day R, Miketic L, Banner B, Whiteside T, Kirkwood JM. Sequentially combined recombinant interferon (rIFN) gamma (g) and alpha (a) in patients (pt) with renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 9:153 (Abstr. 594), 1990.
41. Nair S, **Ernstoff MS**, Whiteside TL, Miketic L, Gemperlein M, Kirkwood JM. Adoptive immunotherapy with adherent LAK (ALAK) cells. Proc Am Soc Clin Oncol 9:200 (Abstr. 775), 1990.
42. Banner BF, Burnbaum JA, Bahnsen RR, **Ernstoff MS**, Auerbach HE. Immunophenotypic markers in renal cell carcinoma. United States and Canadian Academy of Pathology Annual Meeting. Mod Path Mar;3(2):129-34, 1990.
43. Logan T, Gooding W, Kirkwood J, **Ernstoff MS**, Whiteside T, Kaplan S, Vlock D, Tompkins C, Wood D, Nadler P. Biologic response modulation by tumor necrosis factor (TNF) in a phase Ib trial in cancer patients. Am Assoc Cancer Res 32:267, 1991.
44. Kirkwood J, Bryant J, Schiller J, **Ernstoff MS**, Vlock D, Borden E, Herberman R, Blum R, Whiteside T. Determination of phenotypic and functional correlates of interferon gamma (IFNg) therapy of metastatic melanoma in a multi-institutional phase Ib trial (ECOG 4987/4687). Proc Am Soc Clin Oncol 10:218, 1991.
45. Logan TF, Virgi MA, Gooding WE, Bontempo FA, **Ernstoff MS**, Kirkwood JM. Plasminogen activator and its inhibitor in cancer patients administered tumor necrosis factor: Relationship to changes in circulating white blood cells. Clin Res 39(2):436A, 1991.
46. **Ernstoff MS**, Heaney J, Chertoff J, Schned A, Maurer LH, Richardson J, Synder P, Amdur R, Gooding W, Robitzer C and Fukui I. Phase I/II trial of 5 fluorouracil, allopurinol and recombinant interferon a-2b in patients with hormone refractory D2 prostate cancer. Proc AACR 34:1215A, 1993.
47. Lush R, Schwartz R, Logan T, **Ernstoff MS**, Kirkwood J, Yalowich J, Kroboth P. Phase I and pharmacological evaluation of tumor necrosis factor (rHuTNF) administered in combination with etoposide. ASCO, 1993.
48. Kirkwood J, Hunt M, Smith T, **Ernstoff MS**, Borden E, Blum R. A randomized controlled trial of high-dose IFN alfa-2b for high-risk melanoma: The ECOG trial EST-1684. ASCO, 1993.
49. Harris RD, Schned AS, Williams J Chandler, Amdur RJ, **Ernstoff MS**, Heaney JA. Magnetic resonance imaging (MRI) of prostate cancer with histopathological correlation. American Urological Association Annual Meeting, May 1994.
50. Gorsch S, Mannheimer E, Phillips D, Lewis A, Heaney J, Stempkowski L, Schned A, Amdur R, McDonnell C, Harris R, **Ernstoff M**. In vivo and in vitro immunologic responses to prostatic carcinoma cell lines among prostate cancer patients and healthy controls. Proc AACR, (#2973), vol 35, p 499, 1994.
51. Glazier DB, Bahnsen RR, McLeod DG, von Roemeling RW, Messing EM, **Ernstoff MS**. The treatment of superficial bladder cancer with intravesical recombinant human tumor necrosis factor (rHuTHF): An eastern cooperative oncology group study. Presented at the meeting of the American Urological Association, New England Section, Sonesta Beach, Bermuda, September 1994.
53. **Ernstoff MS**, Harris RD, Schned AR, Chertoff JD, Phillips DM, Lewis AP, Hackwell R, Pape L, Amdur R, Noelle R, Heaney JA. Autologous tumor vaccine (ATV) combined with sequential interferon zeta and interferon alpha in the treatment of patients with metastatic renal cell carcinoma. AACR, 1995.
54. **Ernstoff MS**, Kanbour-Shakir A, Bahnsen RR, Tosteson TD, Kuo SM, Phillips D, Mott LA, Oeler T, Lazo JS. Tumor metallothionein expression in patients with ovarian cancer. AACR, 1995.

55. Kirkwood JM, Sosman J, **Ernstoff MS**, Ross M, Gerstner C, Whiteside T, Johnson C. E2690: A study of the mechanism of IFN alfa-2b in high-risk melanoma in the ECOG/Intergroup trial E1690. AACR, 1995.
56. Dawson NA, Conaway M, Winer EP, Lake D, Small EJ, Cooper MR, Green MR, **Ernstoff MS**, Vogelzang NJ. A randomized study comparing standard versus moderately high dose megestrol acetate in advanced prostate cancer: A cancer and leukemia group B study. ASCO, 1996.
57. Cardi, G, Schned, A, Heaney, J, Burns, C, Santi, L, **Ernstoff, MS** Direct evidence that T-cell receptor ζ chain is present in T-cells infiltrating renal cell carcinoma. AACR, Washington, DC, 1996.
58. Cardi G, Dain B, Heaney J, Santi L, Schned A, Phillips D, **Ernstoff MS**. CD45RO Expression in Tumor Infiltrating Lymphocytes (TIL) From Patients (PTS) with Metastatic Renal Cell Cancer (RC). ASCO, Philadelphia, PA, 1996.
59. Anthony SP, Ihnat MA, **Ernstoff MS**, Kaufman PA, Lewis LD, Barth RJ et al. Suppression in Expression of P-Glycoprotein and Other Proteins Associated with Multidrug Resistance (MDR) by Mitomycin C in Metastatic Breast Cancer Patients: Preliminary Results from a Pilot Clinical Trial. Proc. ASCO, Philadelphia, PA, 1996.
60. Spitler LE, Grossbard ML, **Ernstoff MS**, Silver G, Jacobs M, Hayes FA, and Soong SJ. Adjuvant therapy of Stage III and IV malignant melanoma using a macrophage activator, GM-CSF. 2nd International Conference on the Adjuvant Therapy of Malignant Melanoma in March, 1997.
61. **Ernstoff MS**, Branda M, Cardi G, Wallace P, MacCalli C, Phillips D, Castelli C, Parmiani G, Hickey WF. Definition of prostate specific antigen derived peptides that bind HLA-A2 allele. AACR 1997.
62. Spitler LE, Grossbard ML, **Ernstoff MS**, Silver G, Jacobs M, Hayes FA and Soong SJ. Adjuvant therapy of Stage III and IV malignant melanoma using GM-CSF. Chemotherapy Foundation Symposium XV conference on "Innovative Cancer Chemotherapy for Tomorrow", November 12-14, 1997 (submitted).
63. Bennett CL, Tosteson R, **Ernstoff MS**, Ross SD. Maximum androgen blockade with flutamide in prostate cancer: a literature-based meta-analysis of 9 randomized trials and 4,128 patients. ASCO, May 1998.
64. Kirkwood J, Ibrahim J, Sondak V, **Ernstoff M**, Flaherty L, Smith T, et al. Eastern Cooperative Oncology Group, Southwest Oncology Group and Cancer and Leukemia Group B. The E1684 and E1690/S9111/C9190 US Intergroup Postoperative Adjuvant Trials of High and Low-Dose IFNa2b (HD1 and LD1) in Resected High-Risk Primary and Regionally Lymph Node Metastatic Melanoma, Harvard Symposium, Nov 6, 1998.
65. Lewis LD, Kaufman PA, Anthony S, Nervi A, Beaulieu B, MacKay K, Barth, R, **Ernstoff MS** et al, Mitomycin C (MMC) prior to paclitaxel (PCTX) does not alter PCTX Pharmacokinetics, American Society of Clinical Pharmacology and Therapeutics, abstract, April, 1999.
66. Rutter JL, Fleming EL, **Ernstoff M**, Coon CI, Klein C, Ozelius LJ and Brinckerhoff CE. A single nucleotide polymorphism (SNP) in the matrix metalloproteinase-1 (MMP-1) promoter is a marker on 11q22 for loss of heterozygosity (LOH) and may influence tumor progression. Dartmouth Medical School, Hanover, NH and Massachusetts General Hospital and Harvard Medical School. AACR abstract, 1999.
67. Saxman SB, Chapman PB, Meyers MI, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, **Ernstoff MS**, Einhorn LH, Kirkwood JM et al. Hoosier Oncology Group, Memorial Sloan-Kettering Cancer Center, University of Pennsylvania Medical Center, Dartmouth Hitchcock Medical Center and Eastern Cooperative Oncology Group, ASCO, 1999.
68. Bukowski R, **Ernstoff M**, Gore M, Amato R, Rybak ME, Rose E. Phase I study of polyethylene glycol (PEG) interferon alpha-2B (PEG INTROn) in patients with solid tumors. Cleveland Clinic, Dartmouth College, Royal Marsden Hospital, London, MD Anderson Cancer Center, Schering Plough Research Institute. ASCO, 1999.

69. Obrocea M, **Ernstoff MS**, Beaulieu BB, MacKay K, Fisher J, Waugh M, Truman D, Lewis LD. A phase-I clinical and pharmacologic study of interferon alfa-2b (IFN-2b), paclitaxel (PCTX) and carboplatin (CBP) on weekly schedule in patients (pts) with refractory and/or solid tumors. Molecular Targets and Cancer Therapeutics Conf, AACR-NCI-EORTC, 1999.
70. Tretter C, Schwaab T, Heaney J, Barth R, Perry A, Cole B, Schned A, Phillips D, Fisher J, Waugh M, **Ernstoff MS**. Induction of T-Cell precursor frequency in patients with high-risk renal cell carcinoma (RCC) and melanoma treated autologous tumor vaccine and GM-CSF. ASCO, 2000
71. Schwaab T, Tretter CP, Cole BF, Schned AR, Harris RD, Fisher JL, Waugh MG, Phillips DM, Heaney JA, **Ernstoff MS**. Prostate Specific Antigen (PSA)-specific T-cell precursor frequencies in prostate cancer patients with rising PSA treated with granulocyte-macrophage colony-stimulating factor (GM-CSF). ASCO, 2000.
72. Cardi G, Dangelis T, **Ernstoff MS**, Ozer H, Phillips D, Gomella LG. Low expression of FAS (AP-1/CD95)-Receptor in Renal Cell Carcinoma Cells: A Stealth Phenotype in the Tumor Escape Mechanism. Proc AACR 41:3935a, 2000.
73. Kirkwood JM, Sosman JA, **Ernstoff MS**, Ross MA Agarwala SS, Edington HF. Overview of the High-dose IFN α 2b (HDI) in the Therapy of High-risk Resectable Melanoma, submitted, 2000.
74. Gollob J, Flaherty L, Smith J, **Ernstoff M**, Clark, Margolin K, Novik Y Sosman J. A cytokine working group (CWG) Phase II trial of a modified gp100 melanoma peptide (gp100 (209M) and high dose interleukin-2 (HD IL-2) administered Q3 weeks in patients with stage IV melanoma: limited antitumor activity. ASCO, 2001.
75. Margolin K, Atkins MB, Weber J, Dutcher JP, **Ernstoff M**, Smith J, Lathia C, Smith J, Martell RE. Cytokine Working Group, Bayer Pharmaceutical Division, West Haven, CT. Phase I study of BAY 50-4798, an interleukin-2 (IL-2) selective agonist in refractory cancer patients. AACR/EORTC, fall 2001.
76. McDermott D, Flaherty L, Clark J, Weiss G, Logan T, Gordon M, Sosman J, **Ernstoff M**. A Randomized Phase III Trial of High-Dose, Interleukin-2 (HDIL2) Versus Subcutaneous (SC) IL2/Interferon (IFN) in Patients with Metastatic Renal Cell Carcinoma (RCC), for the Cytokine Working Group (CWG) Beth Israel Deaconess Medical Center, Boston, MA. fall 2001.
77. Margolin K, Atkins MB, Weber J, Dutcher JP, **Ernstoff M**, Smith J, Clark J, O'Day S, Flaherty L, Baar J, Sosman J, Thompson JA, Lathia C, Smith J, Martell RE. (Cytokine Working Group), Phase I study of the interleukin-2 selective agonist BAY-50-4798 in patients with advanced melanoma and renal cell carcinoma, ASCO, 2002.
77. Logan TF, Dutcher JP, Flaherty LE, Sosman JA, **Ernstoff MS**, Clark JI, Atkins MB. A Cytokine Working Group (CWG) phase II study of intermediate dose bolus interleukin-2 (IL-2) for renal cell carcinoma (RCC) patients ineligible to receive high dose IL-2 (HD IL-2) due to inadequate organ function, ASCO, 2002.
78. Titus-Ernstoff L, Spencer S, Perry A, Ding J, Harjes J, Gibson J, **Ernstoff M**. Nevi in Relation to Melanoma Risk. Mediterranean Melanoma Conference, 2003.
79. M.S. Mitchell, J. Abrams, M. Kashani-Sabet, J. Thompson, and the Ad Hoc Melanoma Study Group. Interim analysis of a Phase III stratified randomized trial of Melacine + low-dose Intron-A versus high-dose Intron-A for resected Stage III melanoma. ASCO 2003